LakeShore Biopharma Receives $0.86/share Buyout Proposal from Oceanpine Capital.

Oceanpine Capital has submitted a preliminary, non-binding proposal to acquire all outstanding shares of LakeShore Biopharma not already owned for $0.86/share, a 10.3% premium to the August 15 closing price and an 11.4% premium to the 15-day average. The transaction would be funded by rollover equity and available cash, with no financing condition. LakeShore's board will evaluate the proposal. LSB shares are up 1.3% premarket on Monday.

Oceanpine Capital has submitted a preliminary, non-binding proposal to acquire all outstanding shares of LakeShore Biopharma (LSB) that are not currently owned by them, for $0.86 per share. This offer represents a 10.3% premium over the August 15 closing price and an 11.4% premium over the 15-day average closing price. The transaction would be funded through rollover equity and available cash, without any financing condition [1].

The proposal was submitted on August 18, 2025, and LakeShore Biopharma's board of directors has just received it. The board will carefully review and evaluate the proposal to determine the best course of action for the company and its shareholders. The company cautions that there is no assurance that a definitive offer will be made, that an agreement will be executed, or that the proposed transaction will be approved or consummated [1].

LakeShore Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It operates in China, Singapore, and the Philippines and is led by a management team with rich local expertise and global experience in the biopharmaceutical industry [1].

LakeShore Biopharma's shares are up 1.3% premarket on Monday following the announcement of the proposal. The company's last closing price on August 15, 2025, was $0.82 per share, and the average closing price over the last 15 trading days was $0.76 per share [1].

Oceanpine Capital, a professional investment management firm founded in 2018, focuses on long-term value investing in advanced technology, green technology, and life sciences. With assets under management exceeding RMB25 billion (approximately USD3.5 billion), the firm aims to drive technological innovation and provide full-cycle support to its portfolio companies [1].

The preliminary non-binding proposal does not constitute a binding commitment, and no agreement will be created until definitive documentation has been executed and delivered by both parties. LakeShore Biopharma's board of directors will evaluate the proposal independently, and none of the company's directors affiliated with Oceanpine Capital will participate in the consideration of the proposal [1].

References:
[1] https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-receipt-of-a-preliminary-non-binding-proposal-to-acquire-the-company-302532192.html